FINHUB Insights

MCK · Q3 FY26 · Oct 1 – Dec 31, 2025

McKesson Q3 FY26: where the revenue came from and where it went

McKesson Q3 FY26: revenue $106.2B (+11% year over year). Net profit $1.2B. Largest cohort North American Pharmaceutical $88.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2025
Reported
Feb 4, 2026 10-Q
Sankey diagram of McKesson's income statement for Q3 FY26: revenue of $106.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$106.2B +11% year over year
Gross profit$3.7B 3% margin
Operating profit$1.6B 2% margin
Net profit$1.2B 1% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 106.2 100% +11%
North American Pharmaceutical 88.3 83%
Oncology & Multispecialty 13 12%
Medical-Surgical Solutions 3 3% +1%
Prescription Technology 1.5 1% +9%
Other 0.3 0%
Cost of revenue−102.597%
Gross profit3.73% margin+0pp
SG&A−2.12%+0pp
Operating profit1.62% margin+0pp
Tax−0.3
Interest & other costs−0.1
Net profit1.21%+0pp
Filing on EDGAR More quarters of MCK

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters